Samik Pharm Co., Ltd.
KKRX:0149507,530.00
KRW
-830.00
(-9.93%)
ISIN
KR7014950000
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Inchon South Korea
- Website
- samik.co.kr
- Similar Companies
- Business
- Samik Pharm Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the development, manufacturing, and distribution of prescription pharmaceuticals (ETC), over-the-counter (OTC) medications, and health functional products, alongside pharmaceutical contract manufacturing organization (CMO) services. The company organizes its product offerings across several core therapeutic categories: chronic disease treatments, including cardiovascular and antihypertensive agents such as Sezar and Cadenza; lipid-lowering therapies such as Sol and Crezy; antidiabetic medications such as Piocita, Janumax, and Dipaglu; gastrointestinal treatments, including Rebacod; anti-inflammatory analgesics; and systemic antibiotics. In its consumer healthcare and over-the-counter segment, the company produces pediatric nutritional supplements under the Kiddy brand; motion sickness remedies under the Novomin brand; and respiratory and cold preparations under the Maparam brand. In addition to finished dosage manufacturing, Samik Pharm provides contract formulation and commercial manufacturing services across solid, liquid, and syrup dosage forms. The company also engages in biotechnology research and development, developing novel therapeutic candidates such as SIKD1977 for post-herpetic neuralgia, as well as proprietary drug delivery platforms, notably its UniSphero uniform microsphere technology for long-acting injectables and regenerative aesthetic medical devices. Founded in 1973 and headquartered in Incheon, South Korea, Samik Pharm operates production and research facilities in Incheon and markets its products domestically while exporting to international markets in Southeast Asia and East Asia. In recent major company developments, Samik Pharm completed a public listing on the KOSDAQ market in October 2025 through an absorption merger with Hana Financial 28 Special Purpose Acquisition Company (SPAC). Following the listing, the company initiated its Re-Leap 2030 strategic growth plan, expanded investments into a second manufacturing facility in Wonju, Gangwon Province to enhance production capacity, and accelerated commercialization efforts for its UniSphero microsphere platform in long-acting therapeutics and collagen-stimulating medical aesthetics.